Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle
Acta Gastro Enterologica Belgica · 30.03.2026 · 91 (1) · 65
DOI: 10.51821/89.1.14529 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Gastro Enterologica Belgica, online erschienen am 02.03.2026. Verfasst von K Argyriou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Medical School and University Hospital of Larissa, Larissa GR41334, Greece.
Abstract (Originalsprache)
Irritable bowel syndrome with constipation (IBS-C) is a common subtype of functional bowel disorder associated with substantial symptom burden and reduced quality of life. Management typically begins with dietary and lifestyle modification, laxatives, and antispasmodics; however, many patients experience inadequate relief, underscoring the need for more effective therapies. Linaclotide, a synthetic guanylin analog, is an established treatment for IBS-C. By activating guanylate cyclase-C (GCC) receptors on intestinal epithelial cells, it promotes intestinal fluid secretion, accelerates transit, and alleviates visceral hypersensitivity. Randomized controlled trials have demonstrated its efficacy and favorable safety profile, with mild-to-moderate diarrhea and abdominal pain being the most common adverse events. Because clinical trial populations may not fully reflect real-world patient diversity, real-world evidence (RWE) provides valuable complementary data. This review summarizes current RWE on linaclotide in IBS-C, integrating findings from multiple studies to present a comprehensive view of its effectiveness and safety in routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Medical School and University Hospital of Larissa, Larissa GR41334, Greece.
- Medical School and University Hospital of Larissa, Larissa GR41334, Greece.
- Department of Gastroenterology, Medical School and University Hospital of Ioannina, Ioannina GR45500, Greece.
Zitieren
APA
Argyriou, K., Manolakis, A., Tsakiridou, E., Christodoulou, D., Kapsoritakis, A., & Miltiadis, M. (2026). Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle. Acta Gastro Enterologica Belgica, 91(1), 65. https://doi.org/10.51821/89.1.14529
Vancouver
Argyriou K, Manolakis A, Tsakiridou E, Christodoulou D, Kapsoritakis A, Miltiadis M. Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle. Acta Gastro Enterologica Belgica. 2026;91(1):65. doi:10.51821/89.1.14529
BibTeX
@article{Argyriou2026,
author = {Argyriou, K and Manolakis, A and Tsakiridou, E and Christodoulou, D and Kapsoritakis, A and Miltiadis, M},
title = {Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle},
journal = {Acta Gastro Enterologica Belgica},
year = {2026},
volume = {91},
number = {1},
pages = {65},
doi = {10.51821/89.1.14529}
}
EUVIMED